Search hospitals

>

Illinois

>

Chicago

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Claim this profile

Chicago, Illinois 60611

Global Leader in Breast Cancer

Global Leader in Lymphoma

Conducts research for Leukemia

Conducts research for Lung Cancer

Conducts research for Cancer

374 reported clinical trials

11 medical researchers

Photo of Robert H. Lurie Comprehensive Cancer Center at Northwestern University in ChicagoPhoto of Robert H. Lurie Comprehensive Cancer Center at Northwestern University in ChicagoPhoto of Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago

Summary

Robert H. Lurie Comprehensive Cancer Center at Northwestern University is a medical facility located in Chicago, Illinois. This center is recognized for care of Breast Cancer, Lymphoma, Leukemia, Lung Cancer, Cancer and other specialties. Robert H. Lurie Comprehensive Cancer Center at Northwestern University is involved with conducting 374 clinical trials across 288 conditions. There are 11 research doctors associated with this hospital, such as Mark Agulnik, Sunandana Chandra, Seth M. Pollack, and Devalingam Mahalingam, MBBChBAO.

Area of expertise

1

Breast Cancer

Global Leader

Robert H. Lurie Comprehensive Cancer Center at Northwestern University has run 60 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
Stage III
PD-L1 positive
2

Lymphoma

Global Leader

Robert H. Lurie Comprehensive Cancer Center at Northwestern University has run 56 trials for Lymphoma. Some of their research focus areas include:

Stage IV
Stage II
Stage III

Top PIs

Clinical Trials running at Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Breast Cancer

Cancer

Ovarian Cancer

Acute Myeloid Leukemia

Leukemia

Endometrial Cancer

Acute Myelogenous Leukemia

Lymphoma

Lung Cancer

Colorectal Cancer

Image of trial facility.

RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant

for Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Recruiting

2 awards

Phase 3

5 criteria

Image of trial facility.

PC14586

for Solid Tumors

This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.

Recruiting

1 award

Phase 1 & 2

5 criteria

Image of trial facility.

Utidelone + Capecitabine

for Breast Cancer with Brain Metastases

This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receive treatment of utidelone alone or in combination with capecitabine. The objectives both in stage I and stage II are to evaluate the intracranial and systemic efficacy and safety of utdelone plus capecitabine for the treatment of HER2-negative breast cancer patients with brain metastases.

Recruiting

1 award

Phase 2

4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Robert H. Lurie Comprehensive Cancer Center at Northwestern University?

Where is Robert H. Lurie Comprehensive Cancer Center at Northwestern University located?

Who should I call to ask about financial aid or insurance network?

What insurance does Robert H. Lurie Comprehensive Cancer Center at Northwestern University accept?

What awards or recognition has Robert H. Lurie Comprehensive Cancer Center at Northwestern University received?